Mitophagy promotes resistance to BH3 mimetics in acute myeloid leukemia

C Glytsou, X Chen, E Zacharioudakis, W Al-Santli… - Cancer discovery, 2023 - AACR
BH3 mimetics are used as an efficient strategy to induce cell death in several blood
malignancies, including acute myeloid leukemia (AML). Venetoclax, a potent BCL-2 …

[HTML][HTML] Reduced mitochondrial apoptotic priming drives resistance to BH3 mimetics in acute myeloid leukemia

S Bhatt, MS Pioso, EA Olesinski, B Yilma, JA Ryan… - Cancer cell, 2020 - cell.com
Acquired resistance to BH3 mimetic antagonists of BCL-2 and MCL-1 is an important clinical
problem. Using acute myelogenous leukemia (AML) patient-derived xenograft (PDX) models …

Maximal Activation of Apoptosis Signaling by Cotargeting Antiapoptotic Proteins in BH3 Mimetic–Resistant AML and AML Stem Cells

BZ Carter, PY Mak, W Tao, Q Zhang, V Ruvolo… - Molecular cancer …, 2022 - AACR
MCL-1 is known to play a major role in resistance to BCL-2 inhibition, but the contribution of
other BCL-2 family proteins has not been fully explored. We, here, demonstrate the …

[HTML][HTML] Co-targeting of Bcl-2 and mTOR pathway triggers synergistic apoptosis in BH3 mimetics resistant acute lymphoblastic leukemia

S Iacovelli, MR Ricciardi, M Allegretti, S Mirabilii… - Oncotarget, 2015 - ncbi.nlm.nih.gov
Several chemo-resistance mechanisms including the Bcl-2 protein family overexpression
and constitutive activation of the PI3K/Akt/mTOR signaling have been documented in acute …

BH3 mimetics in AML therapy: death and beyond?

C Cerella, M Dicato, M Diederich - Trends in Pharmacological Sciences, 2020 - cell.com
B cell lymphoma 2 (BCL2) homology domain 3 (BH3) mimetics are targeted therapeutic
agents that allow response prediction and patient stratification. BH3 mimetics are …

Combining BH3-mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of acute myeloid leukemia

DM Moujalled, G Pomilio, C Ghiurau, A Ivey, J Salmon… - Leukemia, 2019 - nature.com
Improving outcomes in acute myeloid leukemia (AML) remains a major clinical challenge.
Overexpression of pro-survival BCL-2 family members rendering transformed cells resistant …

[HTML][HTML] AMPK-PERK axis represses oxidative metabolism and enhances apoptotic priming of mitochondria in acute myeloid leukemia

A Grenier, L Poulain, J Mondesir, A Jacquel, C Bosc… - Cell Reports, 2022 - cell.com
AMP-activated protein kinase (AMPK) regulates the balance between cellular anabolism
and catabolism dependent on energy resources to maintain proliferation and survival. Small …

[HTML][HTML] Concomitantly targeting BCL-2 with venetoclax (ABT-199/GDC-0199) and MAPK signaling with Cobimetinib (GDC-0973) in acute myeloid leukemia models

L Han, Q Zhang, C Shi, J Leverson, M Dail, DC Phillips… - Blood, 2015 - Elsevier
Pro-survival molecules including BCL-2 play critical roles in leukemia transformation and
chemoresistance. ABT-199/GDC-0199 (venetoclax) is an orally available BH3-mimetic that …

Multiple BH3 mimetics antagonize antiapoptotic MCL1 protein by inducing the endoplasmic reticulum stress response and up-regulating BH3-only protein NOXA

TC Albershardt, BL Salerni, RS Soderquist… - Journal of Biological …, 2011 - ASBMB
BH3 mimetics are small molecules designed or discovered to mimic the binding of BH3-only
proteins to the hydrophobic groove of antiapoptotic BCL2 proteins. The selectivity of these …

Systematic mapping of BCL-2 gene dependencies in cancer reveals molecular determinants of BH3 mimetic sensitivity

RS Soderquist, L Crawford, E Liu, M Lu… - Nature …, 2018 - nature.com
While inhibitors of BCL-2 family proteins (BH3 mimetics) have shown promise as anti-cancer
agents, the various dependencies or co-dependencies of diverse cancers on BCL-2 genes …